CN113508137A - 一种嵌合抗原受体及其应用 - Google Patents

一种嵌合抗原受体及其应用 Download PDF

Info

Publication number
CN113508137A
CN113508137A CN202080011407.8A CN202080011407A CN113508137A CN 113508137 A CN113508137 A CN 113508137A CN 202080011407 A CN202080011407 A CN 202080011407A CN 113508137 A CN113508137 A CN 113508137A
Authority
CN
China
Prior art keywords
seq
car
cell
antibody
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080011407.8A
Other languages
English (en)
Inventor
杨选明
傅阳心
李范林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Jiaotong University
Original Assignee
Shanghai Jiaotong University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Jiaotong University filed Critical Shanghai Jiaotong University
Publication of CN113508137A publication Critical patent/CN113508137A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

本申请提供一种嵌合抗原受体(CAR)，其中所述CAR包含靶向部分、跨膜结构域、共刺激结构域和胞内信号传导结构域，其中所述靶向部分特异性结合T细胞受体(TCR)的可变区Vα、Vβ和/或它们的片段。

Description

PCT国内申请，说明书已公开。

Claims (44)

  1. PCT国内申请，权利要求书已公开。
CN202080011407.8A 2019-01-29 2020-01-20 一种嵌合抗原受体及其应用 Pending CN113508137A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019100946586 2019-01-29
CN201910094658 2019-01-29
PCT/CN2020/073304 WO2020156335A1 (zh) 2019-01-29 2020-01-20 一种嵌合抗原受体及其应用

Publications (1)

Publication Number Publication Date
CN113508137A true CN113508137A (zh) 2021-10-15

Family

ID=71840112

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080011407.8A Pending CN113508137A (zh) 2019-01-29 2020-01-20 一种嵌合抗原受体及其应用

Country Status (6)

Country Link
US (1) US20220144948A1 (zh)
EP (1) EP3919515A4 (zh)
JP (1) JP2022523502A (zh)
KR (1) KR20210121136A (zh)
CN (1) CN113508137A (zh)
WO (1) WO2020156335A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11696766B2 (en) 2009-09-11 2023-07-11 Tbi Innovations, Llc Methods and devices to reduce damaging effects of concussive or blast forces on a subject
US8900169B2 (en) 2013-03-15 2014-12-02 Tbi Innovations, Llc Methods and devices to reduce the likelihood of injury from concussive or blast forces
WO2017087556A1 (en) 2015-11-16 2017-05-26 Q30 Sports Science, Llc Traumatic brain injury protection devices
BR112018067355B1 (pt) 2016-03-02 2023-04-11 Q30 Sports Science, Llc Sistema para reduzir os efeitos danificantes de forças concussivas ou de choque sobre um sujeito
GB202105682D0 (en) * 2021-04-21 2021-06-02 Imp College Innovations Ltd Chimeric antigen receptor (CAR)-T cells
GB202105686D0 (en) * 2021-04-21 2021-06-02 Imperial College Innovations Ltd Chimeric antigen receptor (CAR)-T cells
WO2024042318A1 (en) * 2022-08-23 2024-02-29 Imperial College Innovations Limited Chimeric antigen receptor (car) to a tcr beta-chain variable region

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101899115A (zh) * 2010-05-17 2010-12-01 中国医学科学院血液学研究所 二硫键稳定的抗cd3-抗cd19微型双功能抗体及其制备方法
CN106068276A (zh) * 2014-03-05 2016-11-02 Ucl商务股份有限公司 具有针对T细胞受体beta恒定区的抗原结合域的嵌合抗原受体(CAR)
WO2016174461A1 (en) * 2015-04-30 2016-11-03 Ucl Business Plc T cell which expresses a gamma-delta t cell receptor (tcr) and a chimeric antigen receptor (car)
US20180022822A1 (en) * 2016-07-13 2018-01-25 Mabimmune Diagnostics Ag Novel anti-fibroblast activation protein (fap) binding agents and uses thereof
CN108026171A (zh) * 2015-06-01 2018-05-11 基因医疗免疫疗法有限责任公司 T细胞受体特异性抗体
WO2018223601A1 (zh) * 2017-06-06 2018-12-13 上海优卡迪生物医药科技有限公司 基于octs-car的抗psca及pdl1双靶向嵌合抗原受体、编码基因及表达载体
CN109071657A (zh) * 2016-01-25 2018-12-21 安进研发（慕尼黑）股份有限公司 包含双特异性抗体构建体的药物组合物
CN109134665A (zh) * 2018-08-24 2019-01-04 深圳普瑞金生物药业有限公司 一种基于单域抗体的bcma嵌合抗原受体及应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103945867B (zh) * 2011-10-27 2018-01-02 Nkt治疗公司 针对iNKT的人类化抗体

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101899115A (zh) * 2010-05-17 2010-12-01 中国医学科学院血液学研究所 二硫键稳定的抗cd3-抗cd19微型双功能抗体及其制备方法
CN106068276A (zh) * 2014-03-05 2016-11-02 Ucl商务股份有限公司 具有针对T细胞受体beta恒定区的抗原结合域的嵌合抗原受体(CAR)
WO2016174461A1 (en) * 2015-04-30 2016-11-03 Ucl Business Plc T cell which expresses a gamma-delta t cell receptor (tcr) and a chimeric antigen receptor (car)
CN108026171A (zh) * 2015-06-01 2018-05-11 基因医疗免疫疗法有限责任公司 T细胞受体特异性抗体
CN109071657A (zh) * 2016-01-25 2018-12-21 安进研发（慕尼黑）股份有限公司 包含双特异性抗体构建体的药物组合物
US20180022822A1 (en) * 2016-07-13 2018-01-25 Mabimmune Diagnostics Ag Novel anti-fibroblast activation protein (fap) binding agents and uses thereof
WO2018223601A1 (zh) * 2017-06-06 2018-12-13 上海优卡迪生物医药科技有限公司 基于octs-car的抗psca及pdl1双靶向嵌合抗原受体、编码基因及表达载体
CN109134665A (zh) * 2018-08-24 2019-01-04 深圳普瑞金生物药业有限公司 一种基于单域抗体的bcma嵌合抗原受体及应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FIELD等: "NNKTT120，an anti-iNKT cell monoclonal antibody, produces rapid and sustained iNKT cell depletion in adults with sickle cell disease", PLOS ONE, vol. 12, no. 2, XP055970482, DOI: 10.1371/journal.pone.0171067 *

Also Published As

Publication number Publication date
KR20210121136A (ko) 2021-10-07
JP2022523502A (ja) 2022-04-25
WO2020156335A1 (zh) 2020-08-06
EP3919515A1 (en) 2021-12-08
EP3919515A4 (en) 2022-11-23
US20220144948A1 (en) 2022-05-12

Similar Documents

Publication Publication Date Title
JP6968389B2 (ja) Ｂｃｍａに結合するキメラ抗原受容体（ｃａｒ）及びその応用
WO2020156335A1 (zh) 一种嵌合抗原受体及其应用
TWI728309B (zh) 一種結合ｂｃｍａ的嵌合抗原受體（ｃａｒ）及其應用
AU2016337525B2 (en) Compositions and methods for inhibition of lineage specific antigens
AU2019279084A1 (en) Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy
AU2017250304A1 (en) Compositions and methods for selective protein expression
CN110760007A (zh) Cd7-car-t细胞及其制备和应用
CN111925451B (zh) 一种靶向bcma的嵌合抗原受体(car)及其应用
CA3117419A1 (en) Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
CN115485289A (zh) 使用工程化的病毒颗粒进行基因递送的方法和组合物
CN115135674A (zh) 树突细胞激活性嵌合抗原受体和其用途
US20190192573A1 (en) Anti-osteosarcoma car-t derived from the antibody oi-3
CN114502723A (zh) 一种经修饰的免疫细胞及其用途
US20240050567A1 (en) Modified immune effector cell and use thereof
WO2023274355A1 (zh) 改造的间充质干细胞和免疫效应细胞联合治疗肿瘤
CN110964112A (zh) 增强抗psca嵌合抗原受体活性的人源化抗体及其应用
WO2021115333A1 (zh) 一种融合蛋白及表达此蛋白的工程化免疫细胞及其应用
WO2023125813A1 (zh) 抗间皮素纳米抗体嵌合抗原受体及其应用
CA3174248A1 (en) Codon-optimized nucleotide sequences encoding an ap-1 transcription factor
WO2024052318A1 (en) Novel dual split car-t cells for the treatment of cd38-positive hematological malignancies
KR20230148837A (ko) Ror1 표적화 키메라 항원 수용체
WO2024076927A2 (en) Novel anti-mesothelin chimeric antigen receptors and modified immune cells
CN118126194A (zh) 靶向cd70的嵌合抗原受体
CN114644716A (zh) 一种抗bxmas1嵌合抗原受体及其修饰的免疫细胞及应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination